GLP-1 TirzepatideRx

Home Sitemap

Sitemap

Every one of the 539 pages on this site, grouped by section, with its URL. The machine-readable versions are linked below.

This page lists every URL we publish. Three machine-readable versions exist alongside it: sitemap.xml for search engines, urls.txt as a plain list you can paste into a crawler or Search Console, and llms-full.txt as an annotated index for answer engines. All four are generated from the same build, so they cannot drift apart.

Home 1 page

News 41 pages

Tirzepatide clinical reference 62 pages

Program reviews 46 pages

Head-to-head comparisons 128 pages

Dose ladder 7 pages

Clinical trial library 21 pages

The Journal 13 pages

Guides 1 page

By state 52 pages

By metro 49 pages

Pharmacy verification 9 pages

Regulatory updates 9 pages

Semaglutide 25 pages

Tools 14 pages

Policies, data and everything else 61 pages

Primary sources

Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.

  1. ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
  2. FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
  3. FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
  4. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
  5. The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.